Innate Pharma (IPHA) Gains from Investment Securities (2019 - 2025)
Historic Gains from Investment Securities for Innate Pharma (IPHA) over the last 5 years, with Q2 2025 value amounting to $98.9 million.
- Innate Pharma's Gains from Investment Securities rose 383015.96% to $98.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $93.1 million, marking a year-over-year increase of 223758.44%. This contributed to the annual value of -$1.4 million for FY2024, which is 1609.51% up from last year.
- Latest data reveals that Innate Pharma reported Gains from Investment Securities of $98.9 million as of Q2 2025, which was up 383015.96% from -$1.4 million recorded in Q4 2024.
- Over the past 5 years, Innate Pharma's Gains from Investment Securities peaked at $98.9 million during Q2 2025, and registered a low of -$2.7 million during Q2 2024.
- For the 4-year period, Innate Pharma's Gains from Investment Securities averaged around $15.5 million, with its median value being -$1.3 million (2024).
- Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 33331.18% in 2024, then skyrocketed by 383015.96% in 2025.
- Quarter analysis of 4 years shows Innate Pharma's Gains from Investment Securities stood at -$1.1 million in 2021, then tumbled by 51.7% to -$1.7 million in 2023, then grew by 16.72% to -$1.4 million in 2024, then skyrocketed by 7035.34% to $98.9 million in 2025.
- Its last three reported values are $98.9 million in Q2 2025, -$1.4 million for Q4 2024, and -$2.7 million during Q2 2024.